BioNTech SE (BNTX)
103.10
+1.14
(+1.12%)
USD |
NASDAQ |
Dec 08, 13:58
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 24.51B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -37.31% |
Valuation | |
PE Ratio | 8.935 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.623 |
Price to Book Value | 1.165 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.0102 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product. |
URL | https://www.biontech.de |
Investor Relations URL | https://investors.biontech.de/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 27, 2024 (est.) |
Last Earnings Release | Nov. 06, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 02, 2022 |
Ratings
Profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product. |
URL | https://www.biontech.de |
Investor Relations URL | https://investors.biontech.de/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 27, 2024 (est.) |
Last Earnings Release | Nov. 06, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 02, 2022 |